These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 37118323)

  • 1. Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a Mechanistic Approach.
    Sabari SS; Balasubramani K; Iyer M; Sureshbabu HW; Venkatesan D; Gopalakrishnan AV; Narayanaswamy A; Senthil Kumar N; Vellingiri B
    Mol Neurobiol; 2023 Aug; 60(8):4547-4573. PubMed ID: 37118323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
    Cheong JLY; de Pablo-Fernandez E; Foltynie T; Noyce AJ
    J Parkinsons Dis; 2020; 10(3):775-789. PubMed ID: 32333549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches.
    Bhattamisra SK; Shin LY; Saad HIBM; Rao V; Candasamy M; Pandey M; Choudhury H
    CNS Neurol Disord Drug Targets; 2020; 19(3):174-183. PubMed ID: 32418534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.
    Xxxx S; Ahmad MH; Rani L; Mondal AC
    Mol Neurobiol; 2022 Jul; 59(7):4466-4487. PubMed ID: 35575870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and Parkinson's Disease: Understanding Shared Molecular Mechanisms.
    König A; Outeiro TF
    J Parkinsons Dis; 2024; 14(5):917-924. PubMed ID: 38995799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. System-based approaches to decode the molecular links in Parkinson's disease and diabetes.
    Santiago JA; Potashkin JA
    Neurobiol Dis; 2014 Dec; 72 Pt A():84-91. PubMed ID: 24718034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
    Cardoso S; Moreira PI
    Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and Parkinson's disease: A new target for disease modification?
    Athauda D; Foltynie T
    Prog Neurobiol; 2016; 145-146():98-120. PubMed ID: 27713036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies modulating insulin resistance in Parkinson's disease: A cross talk.
    Sharma T; Kaur D; Grewal AK; Singh TG
    Neurosci Lett; 2021 Apr; 749():135754. PubMed ID: 33610666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications.
    Tumminia A; Vinciguerra F; Parisi M; Frittitta L
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30355995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin role in Parkinson's disease: a double-sword effect.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Jabir MS; Negm WA; Batiha GE
    Mol Cell Biochem; 2024 Apr; 479(4):975-991. PubMed ID: 37266747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 diabetes mellitus augments Parkinson's disease risk or the other way around: Facts, challenges and future possibilities.
    Faizan M; Sarkar A; Singh MP
    Ageing Res Rev; 2022 Nov; 81():101727. PubMed ID: 36038113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications.
    Hassan A; Sharma Kandel R; Mishra R; Gautam J; Alaref A; Jahan N
    Cureus; 2020 Aug; 12(8):e9853. PubMed ID: 32832307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila.
    Sanz FJ; Solana-Manrique C; Lilao-Garzón J; Brito-Casillas Y; Muñoz-Descalzo S; Paricio N
    FASEB J; 2022 Aug; 36(8):e22432. PubMed ID: 35766235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Type 2 Diabetes in Parkinson's Disease.
    Athauda D; Evans J; Wernick A; Virdi G; Choi ML; Lawton M; Vijiaratnam N; Girges C; Ben-Shlomo Y; Ismail K; Morris H; Grosset D; Foltynie T; Gandhi S
    Mov Disord; 2022 Aug; 37(8):1612-1623. PubMed ID: 35699244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
    Victorino DB; Nejm M; Guimarães-Marques M; Scorza FA; Scorza CA
    Pharmaceut Med; 2021 Jan; 35(1):11-19. PubMed ID: 33409802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes microenvironment promotes the development of Parkinson's disease by activating microglial cell inflammation.
    Zhang B; Song C; Tang X; Tian M; Liu Y; Yan Z; Duan R; Liu Y
    Front Cell Dev Biol; 2024; 12():1422746. PubMed ID: 39050892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.
    Ribarič S
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's Disease, Diabetes and Cognitive Impairment.
    Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.